Amneal Pharmaceuticals 

$16.25
72
+$0.01+0.06% Tuesday 20:00

統計

當日最高
16.33
當日最低
16.01
52週高點
16.61
52週低點
7.67
成交量
1,674,693
平均成交量
-
市值
5.11B
本益比
43.89
股息殖利率
-
股息
-

即將到來

財報

12Aug預期
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
下一步
0.12
0.17
0.22
0.27
預期EPS
0.22473
實際EPS
不適用

財務

2.39%利潤率
有盈利
2020
2021
2022
2023
2024
2025
6.04B營收
144.11M淨利

分析師評級

17.33平均目標價
最高預估為 19.00。
來自過去6個月內的 3 則評分。這不是投資建議。
買入
100%
持有
0%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 AMRX 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Show more...
執行長
Mr. Chirag K. Patel
員工
8300
國家
美國
ISIN
US03168L1052

上市

0 Comments

分享你的想法

FAQ

Amneal Pharmaceuticals 今天的股價是多少?
AMRX 目前價格為 $16.25 USD,過去 24 小時上漲了 +0.06%。在圖表上更密切關注 Amneal Pharmaceuticals 股價表現。
Amneal Pharmaceuticals 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Amneal Pharmaceuticals 的股票以代號 AMRX 進行交易。
Amneal Pharmaceuticals 的股價在上漲嗎?
AMRX 股票較上週上漲 +6.07%,本月上漲 +36.21%,過去一年 Amneal Pharmaceuticals 上漲 +105.7%。
Amneal Pharmaceuticals 的市值是多少?
今天 Amneal Pharmaceuticals 的市值為 5.11B
Amneal Pharmaceuticals 下一次財報日期是什麼時候?
Amneal Pharmaceuticals 將於 August 12, 2026 公布下一次財報。
Amneal Pharmaceuticals 上一季度的財報如何?
AMRX 上一季度的財報為每股 0.27 USD,預估為 0.17 USD,帶來 +59.64% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Amneal Pharmaceuticals 去年的營收是多少?
Amneal Pharmaceuticals 去年的營收為 6.04BUSD。
Amneal Pharmaceuticals 去年的淨利是多少?
AMRX 去年的淨收益為 144.11MUSD。
Amneal Pharmaceuticals 有多少名員工?
截至 June 17, 2026,公司共有 8,300 名員工。
Amneal Pharmaceuticals 位於哪個產業?
Amneal Pharmaceuticals從事於Health & Wellness產業。
Amneal Pharmaceuticals 何時完成拆股?
Amneal Pharmaceuticals 上次拆股發生於 August 26, 2013,比例為 1:25。
Amneal Pharmaceuticals 的總部在哪裡?
Amneal Pharmaceuticals 的總部位於 美國 的 Bridgewater。